GENEVA, November 28, 2017 /PRNewswire/ —
iOnctura SA, a recently founded late stage preclinical immuno-oncology company, announced today the formation of an international Scientific Advisory Board (SAB).
iOnctura is developing a pipeline of selected assets with novel biology that target and modulate mechanisms that drive immunosuppression in the tumour microenvironment (TME) to boost efficacy and maximize the therapeutic potential of checkpoint inhibitors. Such immune-suppression is thought to be one of the main reasons why a considerable number of patients do not respond to first generation checkpoint inhibitors. The company’s lead program, a potentially first in class highly selective PI3K delta inhibitor, is scheduled to enter clinical development in 2018.
The Scientific Advisory Board will closely work with iOnctura’s management team to maximise the potential of iOnctura’s pipeline and rapidly progress its assets through pre-clinical and clinical proof of concept, guided by strong scientific rationale and translational science.
The SAB includes some of the world’s leading experts in tumor immunology and checkpoint inhibitor therapy:
Dr Sergio A. Quezada, Head of Immune Regulation and Tumour Immunotherapy Research Group at University College London Dr James Larkin, Consultant Medical Oncologist at The Royal Marsden, Vice Chair of the Cancer Research UK Clinical Research Committee and Lead of the Uncommon Cancers Theme at The Royal Marsden/The Institute of Cancer Research NIHR Biomedical Research Centre Professor Stuart Farrow, Director of Biology, Cancer Research UK’s Therapeutic Discovery Laboratories. Dr Joern-Peter Halle, Head of External Innovation & Translational Innovation Platform Immuno-Oncology at the biopharma business of Merck KGaA, Darmstadt, Germany
iOnctura, has already built a pipeline of promising programs through its alliances with Merck KGaA, Darmstadt, Germany – which operates its biopharma business as EMD Serono in the US and Canada – and Cancer Research UK, and has entered into a research collaboration with Cancer Research UK’s Therapeutic Discovery Laboratories.
On welcoming the members to the SAB, Catherine Pickering, CEO and co-founder of iOnctura, said: “We are delighted to have attracted this prestigious group of experts to our Scientific Advisory Board. Comprised of world renowned scientists and clinicians, their knowledge and experience in the field of cancer immunology will be invaluable as we rapidly progress our pipeline through pre-clinical development and clinical proof of concept, and will support our goal to maximize the therapeutic potential of checkpoint inhibitors for patients.”
SCIENTIFIC ADVISORY BOARD
Dr Sergio A. Quezada
Dr Quezada earned an undergraduate